Long-term results of endovascular therapy with nitinol stent implantation for TASC II A/B femoro-popliteal artery lesions: 4 Years' experience

Circulation Journal

Volumn 73, Issue 11, 2009, Pages 2143-2147

  Iida, Osamu ^a   Nanto, Shinsuke ^b   Uematsu, Masaaki ^a   Ikeoka, Kuniyasu ^a   Okamoto, Shin ^a   Dohi, Tomoharu ^a   Fujita, Masashi ^a   Nagata, Seiki ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endovascular therapy (EVT); Femoro popliteal artery (FPA); Nitinol stent

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; NITINOL; TICLOPIDINE;

ADULT; AGED; ARTERY LESION; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FEMALE; FEMOROPOPLITEAL ARTERY LESION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPLITEAL ARTERY; RESTENOSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; AGED, 80 AND OVER; ALLOYS; ANGIOPLASTY, BALLOON; ARTERIAL OCCLUSIVE DISEASES; FEMALE; FEMORAL ARTERY; HUMANS; MALE; MIDDLE AGED; POPLITEAL ARTERY; RETROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 73249152787     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0166     Document Type: Article

References (18)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1 - S75.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD): TASC Working Group [TransAtlantic Inter-Society Consensus (TASC)]. J Vasc Surg 2000; 31: S1 - S296.
3. Kamiya C, Sakamoto S, Tamori Y, Yoshimuta T, Higashi M, Tanaka R, et al. Long-term outcome after percutaneous peripheral intervention vs medical treatment for patients with superficial femoral artery occlusive disease. Circ J 2008; 72: 734 - 739.
4. Johnston KW. Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty. Radiology 1992; 183: 767 - 771.
5. Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlböck M, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation 2000; 102: 2674 - 2676.
6. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol 1997; 20: 420 - 425.
7. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. Palmaz stent placement in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc IntervRadiol 2001; 12: 23 - 31.
8. Sabeti S, Schillinger M, Amighi J, Sherif C, Mlekusch W, Ahmadi R, et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: Propensity score-adjusted analysis. Radiology 2004; 232: 516 - 521.
9. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879 - 1888.
10. Rocha-Singh KJ, Jaff MR, Crabtree TR, Bloch DA, Ansel G. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007; 69: 910 - 919.
11. Iida O, Nanto S, Uematsu M, Morozumi T, Kotani J, Awata M, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 2005;69: 1256 - 1259.
12. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48: 144 - 149.
13. Dormandy J, Mahir M, Ascady G, Balsano F, De Leeuw P, Blombery P, et al. Fate of the patient with chronic leg ischaemia: A review article. J Cardiovasc Surg 1989; 30: 50 - 57.
14. Daskalopoulou SS, Pathmarajah M, Kakkos SK, Daskalopoulos ME, Holloway P, Mikhailidis DP, et al. Association between ankle-brachial index and risk factor profile in patients newly diagnosed with intermittent claudication. Circ J 2008; 72: 441 - 448.
15. Hoshino J, Ubara Y, Ohara K, Ohta E, Suwabe T, Higa Y, et al. Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). Circ J 2008; 72: 1495 - 1498.
16. Pentecost MJ, Criqui MH, Dorros G, Goldstone J, Johnston KW, Martin EC, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. Circulation 1994; 89: 511 - 531.
17. Krankenberg H, Schlüter M, Steinkamp HJ, Bürgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: The femoral artery stenting trial (FAST). Circulation 2007; 116: 285 - 292.
18. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005; 45: 312 - 315.